SCHEMBL18655390

SCHEMBL18655390

CC(C)C1Cc2c(O)cc(O)cc2OC1c1cc(O)c(O)c(O)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 5/20 0.67
SNCA P37840 4/20 0.67
KDM4E B2RXH2 3/20 0.67
MAPT P10636 3/20 0.67
RECQL P46063 3/20 0.67
TDP1 Q9NUW8 3/20 0.67
PTGS1 P23219 3/20 0.67
ALDH1A1 P00352 2/20 0.67
HPGD P15428 2/20 0.67
ALOX15 P16050 2/20 0.67
APEX1 P27695 2/20 0.67
HSD17B10 Q99714 2/20 0.67
CNR1 P21554 2/20 0.67
RAD52 P43351 2/20 0.67
DYRK1A Q13627 5/20 0.55
HSP90AB1 P08238 5/20 0.55
MMP2 P08253 4/20 0.55
MMP7 P09237 4/20 0.55
MMP14 P50281 4/20 0.55
MET P08581 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12188003 0.82 BACE1 (0.72) BACE1SNCAKDM4EMAPTRECQL
SCHEMBL22769206 0.82 BACE1 (0.72) BACE1SNCAKDM4EMAPTRECQL
SCHEMBL12379706 0.82 BACE1 (0.72) BACE1SNCAKDM4EMAPTRECQL
SCHEMBL20991943 0.81 DYRK1A (0.64) BACE1SNCAKDM4EMAPTRECQL
Gallocatechin SCHEMBL3872234 0.80 BACE1 (1.00) BACE1SNCAKDM4EMAPTRECQL
Epigallocatechin SCHEMBL20203645 0.80 BACE1 (1.00) BACE1SNCAKDM4EMAPTRECQL
Epigallocatechin SCHEMBL1972940 0.80 BACE1 (1.00) BACE1SNCAKDM4EMAPTRECQL
Epigallocatechin SCHEMBL12285364 0.80 BACE1 (1.00) BACE1SNCAKDM4EMAPTRECQL
Epigallocatechin SCHEMBL19553 0.80 BACE1 (1.00) BACE1SNCAKDM4EMAPTRECQL
Epigallocatechin SCHEMBL1972938 0.80 BACE1 (1.00) BACE1SNCAKDM4EMAPTRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10420815-B2 Combinational therapy for synergistic inhibition of gram-positive and gram-negative bacteria THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2019-09-24 US disclosed
WO-2017045060-A1 COMBINATIONAL THERAPY FOR SYNERGISTIC INHIBITION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2017-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10420815-B2 Combinational therapy for synergistic inhibition of gram-positive and gram-negative bacteria NRDC, BPGM, TGM3 BACE1 2908/4885SNCA 4588/4885KDM4E 4202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.